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Abstract
Background: Visualization during gastrointestinal endoscopy requires distention of the bowel
lumen. Carbon dioxide (CO2) insufflation decreases post-procedure abdominal discomfort and
distension after colonoscopy, but there have been few published studies on its use in endoscopic
retrograde cholangiopancreatography (ERCP).
Objective: To assess the safety and efficacy of CO2 insufflation during ERCP.
Design: Double-blind, controlled, randomized trial
Setting: Tertiary care referral center.
Patients: Consecutive patients referred for ERCP, excluding those with known CO2 retention or
taking chronic opiate medications.
Interventions: Insufflation of CO2 vs insufflation of air.
Main outcome measurements: Primary outcomes were abdominal pain assessed on a visual
analogue scale, and abdominal distension. Secondary outcomes included transcutaneous CO2 levels
(pCO2) and procedural complications.
Results: 74 patients were analyzed, 38 in the air group and 36 in the CO2 group. Pain scores were
similar in both groups one-hour post-procedure (16 vs 11mm in the CO2 and air groups, respectively;
p = 0.29), as well as over the subsequent 24 hours. There were also no significant differences between
groups in abdominal distension or pCO2 levels. There were 13 patients with complications in the air
group and 5 in the CO2 group (p = 0.04; nominal significance removed by Bonferroni correction),
though most were minor in nature.
Limitations: Single center.
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Conclusions: The use of CO2 for insufflation during ERCP was safe in a tertiary care referral
population. However, use of CO2 during ERCP did not lead to decreased post-procedural pain or
less abdominal distension, so its role in this procedure remains in question.
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Introduction
Adequate visualization during gastrointestinal endoscopy requires distention of the bowel
lumen. While it is standard practice in the United States to use ambient, or “room” air for this
purpose, there are potential disadvantages. After insufflation, air is not absorbed and must be
passed from the GI tract, which can lead to bowel distension and abdominal discomfort. Carbon
dioxide (CO2) has been previously suggested as an alternative to air,1-7 and subsequent studies
have examined its safety and efficacy as compared to air.8-19 Results have been consistent,
particularly in colonoscopy but also with flexible sigmoidoscopy and double-balloon
enteroscopy, that the use of CO2 insufflation leads to less post-procedural abdominal pain and
distension.20 The explanation for this is that CO2 is rapidly absorbed from the bowel, thus
allowing the bowel to deflate quickly and decreasing patient discomfort.
Though the use of CO2 for endoscopic retrograde cholangiopancreatography (ERCP) has been
less well studied, two recent randomized control trials suggested that patients experienced less
pain and distention with CO2 as compared to air.18, 19 Because ERCP is arguably the
endoscopic procedure with the highest risk of complications,21, 22 and because ERCP can be
a longer procedure with higher doses of sedation medications administered and potentially
greater amount of air insufflated, it is an attractive candidate for CO2 use. However, questions
remain about the safety and efficacy of CO2 insufflation during ERCP.
The aims of this randomized, controlled, double-blind trial were to assess the safety, as
measured by transcutaneous partial arterial pressure of CO2 (pCO2) levels, and efficacy, as
measured by post-procedural abdominal pain and distention, of CO2 insufflation during ERCP.
We hypothesized that CO2 insufflation would be as safe as air insufflation, and that it would
be associated with less post-procedural abdominal pain and distension.
Methods
Participants
Between June 2008 and January 2009, all consecutive adult patients undergoing ERCP at
University of North Carolina (UNC) Hospitals GI procedures unit were screened for
recruitment. Patients were excluded if they: were ≤ 18 years old; had chronic obstructive
pulmonary disease (COPD) requiring oxygen; had known CO2 retention (defined as diagnosed
in the medical record); had a same-day second endoscopy that would require additional bowel
insufflation; required general anesthesia for the procedure; used chronic opiates for pain
(defined as the use of a long-acting opiate at least daily for greater than 45 days); were unable
to read or understand English; were pregnant; were incarcerated, or had any medical instability
making the procedure unsafe. All participants provided informed consent prior to study
enrollment.
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Randomization was 1:1 by variable block size using a computer-generated sequence.
Allocation was concealed with opaque envelopes. A research nurse not involved with patient
recruitment or data collection determined assignment and masked the equipment. The
procedure room set-up was the same for every study procedure regardless of gas used. Both
the CO2 insufflator (see below) and the air button and indicator on the scope processor were
covered so the settings and type of gas being insufflated could not be determined. All patients
were tracked with a unique identifier unrelated to their treatment assignment. Overall, patients,
endoscopists, ERCP nurses, and recovery nurses, as well as the data collectors and analysts
(for the initial analysis) were all blinded as to study status.
ERCP, CO2 insufflation, and capnography
ERCP and patient monitoring were performed as per standard protocol at our center. Conscious
sedation with fentanyl and midazolam was administered. The procedure was performed at the
discretion of the endoscopist as dictated by the clinical indication and findings. For the
intervention, patients either received standard air insufflation through the scope processor, or
CO2 insufflation.
CO2 was insufflated using the Olympus Endoscopic CO2 Regulation Unit (UCR, Olympus
Medical, Central Valley, PA; Figure 1A), an FDA-approved device. This unit connects to a
CO2 tank and dispenses CO2 through the gas outlet on the front of the machine. In turn, this
connects to a specialized water bottle lid (Figure 1B) that also has a standard adaptor for
attaching the water bottle to the scope (Figure 2). The flow rate of CO2 is designed to be similar
to the flow rate of air when the processor is set on “high”, so the endoscopist does not detect
a difference at the level of the air button. The insufflator was turned on for all procedures and
is essentially silent; when it is activated to deliver flow, there is no appreciable additional noise.
Transcutaneous capnography was performed using the TOSCA 500 monitor (Radiometer
America Inc., Westlake, OH). This non-invasive monitor was selected because it has previously
been shown to measure the pCO2 with outstanding accuracy as compared with blood gas
assessment.23, 24
Outcomes
The primary outcomes were abdominal pain, as recorded on a 100 mm visual analogue scale
(VAS) and measured pre- and 1, 3, 6, and 24-hours post-ERCP, and abdominal girth as
measured at the level of the umbilicus pre- and immediately post-ERCP (defined as when the
patient was transferred from fluoroscopy table to stretcher) by a research assistant blinded to
allocation. These time frames were picked for comparison to previously conducted studies in
the field.9, 11, 12, 16, 18 The 1-hour post-procedure time point was the main outcome of interest
overall, and was assessed post-procedure either in the recovery area, in the waiting room for
patients who were already discharged, or on the hospital ward for inpatients. Patients were
given a form with the pain scales for the 3, 6, and 24 hour time points and returned them via
mail. All patients were contacted approximately 24 hours post-procedure to assess for
complications.
The main secondary outcomes were transcutaneous pCO2 levels (baseline, maximum, and
mean), and procedural complications. Complications included: respiratory depression
requiring reversal agents; CO2 retention with pCO2 > 55; hypotension requiring fluid boluses,
reversal agents, or pressors; cardiac arrhythmias; immediate and delayed bleeding (defined as
requiring endoscopic intervention for hemostasis); cholangitis; pancreatitis (defined by
standard conventions25); perforation; and death. Delayed complications were assessed with a
follow-up phone call 24 hours post-procedure. Other outcomes of interest included time to
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discharge from the recovery room, procedure costs as measured by billing charges, medication
doses, time to cannulation (measured as time from cannula deployment to fluoroscopy
confirmed cannulation), cannulation success rate, total ERCP time, and procedure success rate.
Intra- and post-procedure data collection was performed by a research assistant or the lead
author, all of whom were blinded as to patient allocation.
Data were also collected for other factors of interest such as patient demographics, body mass
index (BMI), ERCP indication, final diagnosis, whether the patient had undergone a prior
ERCP, comorbidities, surgical history, and, for procedures in which a fellow was involved,
the fellow experience level (prior number of ERCPs).
Statistical analysis
Analyses were performed on an intention-to-treat basis for patients who received the
intervention. Data analysts were unmasked as to treatment assignment only after data
collection, editing for quality, and initial analysis (using blinded study groups) were complete.
Characteristics of the study groups were compared with a t-test for continuous variables and
chi-square (or Fisher's exact test, when appropriate) for categorical variables. General
estimating equations (GEE) were used to analyze the serial pain scores as repeated measures
over time. Multiple linear regression was used to adjust for potential confounding factors.
Statistical significance was taken as p < 0.05. In recognizing that there were several statistical
tests performed on some outcome data arising from individual patients, the uncorrected p-
values are presented along with the effect of correction utilizing the method of Bonferroni
whenever that correction would remove statistical significance at the p < 0.05 level. All
analyses were performed with Stata version 9 (StataCorp, College Station, TX).
Sample size was determined by power calculation. We aimed to detect what we felt would be
a clinically significant difference in the primary outcome of 1-hour post-procedure abdominal
pain, specifically a 20mm decrease in the VAS. Based on data available at the time of study
design,6, 9, 11, 12, 16, 18 we estimated that the room air group would have a mean VAS of 40mm
and the CO2 group would have a mean score of 20mm. To detect this difference with a power
of 0.9 and alpha of 0.05, complete data would be required on at least 33 patients per group, so
assuming drop-out, our recruitment goal was 74 patients total.
This study was approved by the UNC Institutional Review Board. It was an investigator-
initiated trial, funded in part by Olympus. Study design and reporting complied with the
CONSORT statement.26 This trial was registered at www.clinicaltrials.gov (NCT00685386).
Results
Patient and ERCP characteristics
Of the 157 patients assessed for eligibility, 78 patients were randomized and 74 were included
in data analysis (Figure 3). Three of the four patients not included were found to be ineligible
after randomization (they were undergoing a second endoscopic procedure that day); technical
difficulties precluded patient participation in the other procedure.
The baseline characteristics were similar across the study groups, including demographics,
BMI, comorbidities, previous surgeries, and the proportion of patients who had undergone
prior ERCP (Table 1).
ERCP indications were also similar in both study groups, as was the proportion of cases in
which a GI fellow was involved and the number of cases in which sphincterotomy was
performed (Table 2). The most common ERCP indications were choledocholithiasis,
pancreatitis, and abnormal LFTs. While there were trends towards some differences between
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the groups, for example more stents were placed in the air group (34% vs 19% in the CO2
group), there were more normal cholangiograms in the air group (16% vs 6% in the CO2 group),
and there was less choledocholithiasis in the air group (21% vs 42%), these were not statistically
significant.
Abdominal pain and distension
For the primary outcome of abdominal pain, there were no significant differences in baseline
scores (Table 3). One-hour post-procedure, the pain score was slightly higher in the CO2 group
as compared to the air group (16 vs 11 mm; p = 0.29). Over the following 24 hours, there were
also no significant differences in pain scores at any of the individual time points, or when
considered as measurements over time on GEE analysis (p = 0.52; Figure 4).
For abdominal distension, there were no significant differences between the two groups before
or after ERCP, and abdominal girth did not change appreciably in either group; there was a
mean increase in girth in both groups of just under 1 cm (p = 0.96; Table 3).
CO2 levels and complications
For pCO2 levels, the groups were approximately equal at baseline at 40 mmHg (Table 3).
Patients in both the air and CO2 group had an increase in pCO2 during the procedure, with the
air group having slightly higher maximum levels (50 vs 49 mmHg), but these were not
statistically significant (p = 0.56).
Overall, there were 13 patients with complications in the air group and 5 in the CO2 group (p
= 0.04; nominal significance removed by correction for multiple testing of data; Table 3),
though most of these were minor. Two of the complications in the air group were related to
respiratory depression and required reversal agents; there were no respiratory events in the
CO2 group. There were 8 patients in the air group and 5 in the CO2 group that reached the
complication threshold of pCO2 > 55. Rates of pancreatitis were approximately the same
between the groups.
Other outcomes
While the mean fentanyl dose was similar between groups, the midazolam dosing was
somewhat higher in the air group (11 vs 9 mg; p = 0.08; Table 3). Cannulation rate was similar
between the groups, but cannulation time was longer in the CO2 group (8 vs 4 minutes; p =
0.05); total procedure times were similar between the two groups. The mean time to discharge
from recovery was almost 12 minutes shorter in the CO2 group than in the air group (67 vs 79
minutes), but this was not statistically significant (p = 0.12). Finally, there was no difference
between groups in the cost of the procedure.
Discussion
CO2 insufflation during ERCP seems logical. Because procedure times can be long and
sedation doses high, there may be greater volumes of gas insufflated required to maintain
visualization of the lumen. We performed a randomized, double-blind, controlled trial to assess
the safety and efficacy of CO2 insufflation during ERCP. Based on prior literature, we expected
CO2 insufflation to be safe and associated with decreased post-procedural abdominal pain and
distension as compared to air insufflation. Our results, however, showed that while CO2 was
safe to use, there were no significant differences between the air and the CO2 group for the
primary outcomes of abdominal pain and distension. This is in contrast to two recent clinical
trials examining the same issue.
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In the first trial,18 Bretthauer and colleagues randomized 118 patients to either air or CO2
insufflation for ERCP. Patients with COPD were excluded, and midazolam with or without
pethidine was used for sedation. Abdominal pain was measured with a 100mm VAS before
and 1, 3, 6, and 24-hours post-procedure, abdominal distension was assessed by abdominal x-
ray, and transcutaneous pCO2 levels were measured in 62 patients. In the second trial,19 Maple
and colleagues randomized 100 patients to the same intervention, but used propofol for
sedation. They also excluded patients with COPD as well as those with significant pre-
procedure pain. Abdominal pain was measured with a 10 point VAS before the procedure, on
arrival to recovery, on discharge, and approximately 24-48 hours post-procedure. Abdominal
girth was measured directly, but pCO2 levels were not recorded. Despite the methodologic
differences in these studies and the use of different CO2 insufflation devices, the results were
similar: there was less pain and distension in the pCO2 group as compared to the air group.
How can we interpret the results from our study in the context of the two prior ERCP trials, as
well as the findings from trials of other endoscopic modalities?6, 9-12, 16-18, 20, 27 There are
several possibilities. First, we detected a smaller than expected effect size. The study was
powered for pain scores in the 20-40 mm range, with a 20mm decrease in VAS which we felt
would be clinically meaningful, not the 10-20 mm range that we observed, with score changes
of 5-10 mm. Second, pain-assessment 1-hour post-ERCP may have been too soon given the
midazolam and fentanyl doses administered. In particular, doses of midazolam were higher in
the air group, and this may explain the lower than expected 1-hour scores in that group. The
sedation protocol is a major difference between our study and that of Maple and colleagues.
Third, variation in measurement of abdominal girth may have obscured differences between
the study groups, particularly when previously reported differences are on the magnitude of
2-3 cm.19
Because of these reasons, and because it was possible that our heterogenous patient population
could mask an effect in subgroups, we performed a sensitivity analysis. However, regardless
of whether we stratified by a biliary or pancreatic indication for ERCP, by baseline pain score,
by presence of post-ERCP pancreatitis, or if we controlled for possible confounding factors,
we did not detect a difference in outcomes. Therefore, because we feel the design of this trial
was methodologically sound, it appears that CO2 insufflation was not effective for decreasing
abdominal pain or distension in our population of unselected patients undergoing ERCP for a
wide range of indications at a tertiary care referral center.
There are several other findings of note in our study, however. First, we generated safety data
and pCO2 levels on all patients in the study and showed that CO2 insufflation was well tolerated.
Because pCO2 levels rose in both groups, the increase was likely attributable to the effect of
sedation, rather than to the effect of CO2 insufflation. Moreover, as compared to almost all
prior studies, we did not exclude all patients with COPD or obstructive sleep apnea from
participating. This is important information which speaks to the tolerability of CO2 insufflation
in patients with comorbidities. In addition, while CO2 monitoring during ERCP with air
insufflation has been shown to decrease respiratory complications,28 given the safety data we
have presented, we do not feel CO2 insufflation in and of itself would require routine
capnography. A final point is that though not statistically significant, time to discharge from
recovery was somewhat shorter in the CO2 group, and future studies could address in more
detail whether CO2 insufflation could impact the efficiency of GI procedure units where
fentanyl and midazolam are used.
In conclusion, the use of CO2 for insufflation during ERCP was safe in a heterogenous tertiary
care referral population. The mild rise we observed in pCO2 in both groups was not attributable
to CO2 insufflation, but rather to conscious sedation. We feel that this is the most extensive
safety data using pCO2 levels reported to date for use of CO2 in GI endoscopy, and in contrast
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to other studies, we included patients with pulmonary disease. Finally, because use of CO2
during ERCP did not lead to decreased post-procedural pain or less abdominal distension,
which were the primary outcomes of this study, its role in this procedure for these purposes
remains in question.
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(A) The Olympus UCR Endoscopic CO2 Regulation Unit (UCR, Olympus Medical, Central
Valley, PA. There is a power button (lower left side), a gas supply indicator lamp, a button in
the center of the device that starts and stops the flow of CO2, and a gas flow indicator. The
back of this unit connects to a CO2 tank, and CO2 is dispensed through the gas outlet on the
lower right side of the front of the machine. This, in turn, connects to the lid of a specialized
water bottle (B) that also has a standard adaptor which connects the water bottle to the scope.
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The study set up. The CO2 insufflator is connected to the CO2 tank as well as to the specialized
water bottle lid. For all cases in the study, both the insufflator and the air indicator on the scope
processor were completely covered in order to mask treatment assignment.
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CONSORT patient flow diagram. Of the patients not meeting inclusion criteria, 2 were known
CO2 retainers, 6 were unable to provide consent due to dementia, 9 were medically unstable,
5 required general anesthesia, 9 were on chronic opioids, 4 were non-English speaking, 4 were
< 18 years old, 3 had Billroth II post-surgical anatomy precluding use of the duodenoscope, 1
was incarcerated, and 5 were scheduled for other non-ERCP procedures. The 16 cases excluded
for other reasons included 5 patients who were screened but did not come for their appointment,
and 11 patients who were missed for recruitment. Of the 4 patients who were randomized but
not included, 3 were found to be ineligible after randomization (they were undergoing a second
endoscopic procedure that day), and technical difficulties precluded patient participation in the
other procedure.
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Abdominal pain scores as measured on a 100 mm VAS before and 1, 3, 6, and 24-hours post-
ERCP. The air insufflation group is in blue and the CO2 group is in green. The arrow points
to the primary outcome at 1 hour post-procedure. As measured by GEE, there is no difference
between pain scores over the time course of the study.
Dellon et al. Page 13

























Dellon et al. Page 14
Table 1






Mean age (years (SD); range) 59.7 (16.6) (18-90) 60.1 (15.0) (26-84) 0.90
Female (n, %) 18 (47) 18 (50) 0.82
Race (n, %)
 White 27 (71) 26 (72) 0.56
 African-American 11 (29) 9 (27)
 Hispanic 0 (0) 1 (3)
Mean BMI (kg/m2 (SD); range) 27.4 (7.2) (19-62) 25.5 (5.8) (17-44) 0.21
Comorbidities (n, %)
 COPD 2 (5) 3 (8) 0.60
 Coronary artery disease 5 (13) 6 (17) 0.67
 Hypertension 15 (39) 19 (53) 0.25
 Diabetes 11 (29) 11 (31) 0.88
 Obstructive sleep apnea 1 (3) 2 (6) 0.52
Previous surgeries (n, %)
 Any prior abdominal surgery 24 (63) 22 (61) 0.86
 Gastric (Heller; Nissen; etc) 0 (0) 0 (0) --
 Cholecystectomy 15 (39) 14 (39) 0.96
 Bowel resection 2 (5) 3 (8) 0.60
 Liver transplantation 5 (13) 4 (11) 0.79
 Hysterectomy 5 (13) 4 (11) 0.79
 Other† 8 (21) 4 (11) 0.25
Prior ERCP (n, %) 11 (29) 15 (42) 0.25
Prior sphincterotomy (n, %) 4 (36) 4 (27) 0.60
Abbreviations: BMI = body mass index; COPD = chronic obstructive pulmonary disease
*
By t-test for continuous variables and Chi-square (or Fisher's exact test) for categorical variables.
†
Other surgeries include: appendectomy (3), hernia repair (2), retroperitoneal mass resection, Roux-en-Y cyst-jejunostomy, pancreatic debridement,
enterotomy repair during cholecystectomy, mesoatrial shunt, ovarian cystectomy, abdominal aortic aneurysm repair.





















ERCP main indication – general (n, %)
 Biliary 32 (84) 27 (75) 0.33
 Pancreatic 6 (16) 9 (25)
ERCP all indications – detailed (n, %)†
 Choledocholithiasis 9 (24) 13 (36) 0.24
 Pancreatitis 5 (13) 8 (22) 0.31
 Bile leak 2 (5) 2 (6) 0.96
 Jaundice 1 (3) 1 (3) 0.97
 Abnormal LFTs 17 (45) 8 (22) 0.04
 Mass 2 (5) 4 (11) 0.36
 Post-liver transplant evaluation 5 (13) 4 (11) 0.79
 Biliary stricture 3 (8) 3 (8) 0.95
 Question PSC 4 (11) 3 (8) 0.75
 Stent change 3 (8) 7 (19) 0.15
 Cholangitis 3 (8) 1 (3) 0.33
 Biliary dilation 4 (11) 2 (6) 0.43
 Choledochal cyst 1 (3) 0 (0) 0.33
Fellow present in case (n, %) 34 (89) 33 (92) 0.75
 Experience: fellow case number (mean (SD)) 80.5 (60.6) (1-199) 88.8 (59.7) (3-200) 0.57
Sphincterotomy performed (n, %) 19 (50) 18 (50) 0.99
Stent placed (n, %) 13 (34) 7 (19) 0.15
Final diagnosis (%)
 Normal 6 (16) 2 (6) 0.16
 Choledocholithiasis 8 (21) 15 (42) 0.06
 Biliary sludge 0 (0) 1 (3) 0.30
 Pancreatitis 3 (8) 4 (11) 0.64
 Bile duct leak 1 (3) 0 (0) 0.33
 Pancreatic duct leak 1 (3) 1 (3) 0.97
 Mass 2 (5) 4 (11) 0.36
 Biliary stricture 9 (24) 4 (11) 0.16
 Cholangitis 1 (3) 0 (0) 0.33
 Ampullary stenosis 2 (5) 0 (0) 0.16
 PSC 3 (8) 1 (3) 0.33
 Stent change 0 (0) 1 (3) 0.30
 Aborted procedure 1 (3) 2 (6) 0.52
 Other‡ 1 (3) 1 (3) 0.97
Abbreviations: LFT = liver function tests; PSC = primary sclerosing cholangitis
*
By t-test for continuous variables and Chi-square (or Fisher's exact test) for categorical variables.













Dellon et al. Page 16
†
Percentages total more than 100%, as some patients had more than one ERCP indication.
‡
Other final diagnoses include: stent migration into bile duct, and pancreatic stent migration out of the pancreatic duct.
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Table 3
Effects of air insufflation vs CO2





Mean abdominal pain scores (SD)
 Prior to procedure 10.5 (21.0) 12.8 (19.6) 0.63
 1-hr post procedure 10.8 (19.3) 16.4 (25.2) 0.29
 3-hr post (nAir = 34; nCO2 = 32) 22.3 (27.8) 20.8 (32.2) 0.95
 6-hr post (nAir = 34; nCO2 = 32) 19.5 (26.7) 18.3 (25.4) 0.85
 24-hr post (nAir = 34; nCO2 = 32) 15.5 (24.0) 15.0 (24.7) 0.94
Mean abdominal girth (cm) (SD)
 Pre-procedure 105.5 (16.6) 101.5 (15.1) 0.28
 Post-procedure (nA = 36; nB = 36) 106.2 (17.4) 102.2 (14.7) 0.30
 Change in abdominal girth (cm) 0.8 (4.8) 0.7 (3.8) 0.96
Secondary outcomes
CO2 safety data (levels in mmHg)
 Mean baseline CO2 level (SD) 40.5 (6.2) 40.3 (4.6) 0.89
 Mean CO2 level (SD) 46.1 (8.8) 45.2 (5.7) 0.61
 Maximum CO2 level (mean (SD)) 50.0 (11.8) 48.7 (6.4) 0.56
 Mean change in CO2 level (SD) 9.4 (10.1) 8.8 (4.8) 0.60
Mean fentanyl dose (mcg) (SD) 162.2 (58.6) 155.6 (66.8) 0.65
Mean midazolam dose (mg) (SD) 10.7 (4.5) 9.1 (3.1) 0.08
Promethazine used (n, %) 6 (16) 6 (17) 0.92
 Mean promethazine dose (mg) (SD) 25.0 (0) 17.0 (6.2) 0.01
Glucagon used (n, %) 22 (58) 24 (67) 0.44
 Mean glucagon dose (mg) (SD) 0.3 (0.2) 0.5 (0.3) 0.003
Mean cannulation time (mins) (SD) 4.3 (3.9) 8.1 (10.4) 0.05
Cannulation success rate (n, %) 36 (95) 33 (92) 0.60
Mean total procedure time (mins) (SD) 35.1 (18.7) 39.3 (20.2) 0.35
Mean recovery discharge time (mins) (SD) 78.8 (37.9) 67.4 (19.7) 0.12
Mean procedure cost (dollars) (SD) 7000 (2560) 7170 (2200) 0.76
 Mean equipment costs 2000 (1390) 1860 (1340) 0.67
 Mean radiology costs 94 (42) 96 (36) 0.83
 Mean hospital costs 2420 (550) 2570 (320) 0.14
 Mean physician costs 2490 (1350) 2630 (1070) 0.63
Complications (n, %)†
 Patients with any complication 13 (34) 5 (14) 0.04††
 Respiratory depression 2 (5) 0 (0) 0.16
 CO2 retention (max level > 45) 22 (58) 25 (69) 0.30
 CO2 retention (max level > 50) 18 (47) 15 (42) 0.62
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 CO2 retention (max level > 55)‡ 8 (22) 5 (15) 0.49
 Hypotension 0 (0) 0 (0) --
 Cardiac arrhythmia (brady to 52)# 1 (3) 0 (0) 0.33
 Immediate bleeding 0 (0) 0 (0) --
 Delayed bleeding 0 (0) 0 (0) --
 Cholangitis 0 (0) 0 (0) --
 Pancreatitis 2 (5) 1 (3) 0.57
 Perforation 0 (0) 0 (0) --
 Death 0 (0) 0 (0) --
 Other** 3 (8) 0 (0) 0.08
*
By t-test for continuous variables and Chi-square (or Fisher's exact test) for categorical variables.
†
Complications total more than 13 because several patients have more than one event.
‡
Only CO2 > 55 was considered a complication.
#
The arrhythmia was bradycardia to a nadir of 52 beats per minute; no atropine administered.
**
Other complications include: one patient fell in recovery and bumped head but had no injury; one patient had a post-procedure fever, was admitted
and observed for 24 hours, but had no localizing infection and the fever resolved; and one patient had post-procedure abdominal pain, was admitted
and observed for 24 hours, but had no structural cause of the pain, which subsequently resolved.
††
P-value for a single test of hypothesis; however, correction for multiple testing removes this nominal statistical significance
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